Tag Archives: AUTO6 NG

Five New Autolus CAR-T Products to Enter the Clinic in 2021; AUTO1’s ALL Market Opportunity; Autolus Q4 2020 Earnings Call Summary

On Thursday, March 4, Autolus held their Q4 2020 earnings presentation (press release / slides). Management presented AUTO1’s possible market strategy in adult ALL and updated several clinical milestones. Of note, Autolus’s cash runway has been extended from 2022 to H1 2023. Below, Celltelligence provides insights into Autolus’s pipeline diversification and AUTO1’s commercial opportunity.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.